Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation - The NCT Neuro Master Match (N 2 M 2) pilot study

Neuro-Oncology

Volumn 20, Issue 6, 2018, Pages 826-837

  Pfaff, Elke ^a,b   Kessler, Tobias ^a,b   Balasubramanian, Gnana Prakash ^a,b   Berberich, Anne ^a,b   Schrimpf, Daniel ^a,b   Wick, Antje ^b   Debus, Jürgen ^a,b,c   Unterberg, Andreas ^b   Bendszus, Martin ^d   Herold Mende, Christel ^b   Capper, David ^e   Schenkel, Irini ^a   Eisenmenger, Andreas ^a   Dettmer, Susan ^a   Brors, Benedikt ^a,b,f   Platten, Michael ^a,g   Pfister, Stefan M ^a,b   Von Deimling, Andreas ^a,b   Jones, David T W ^a   Wick, Wolfgang ^a,b   Sahm, Felix ^a,b   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Heidelberg Institute for Radiation Oncology (HIRO)   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f DKTK   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

glioblastoma; MGMT; N2M2; precision oncology

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENZYME REGULATION; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; MALE; MGMT GENE; MICROARRAY ANALYSIS; MIDDLE AGED; PILOT STUDY; PROMOTER REGION; RNA SEQUENCE; WHOLE EXOME SEQUENCING; ALGORITHM; BRAIN TUMOR; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE GENOME SEQUENCING;

ALGORITHMS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING;

EID: 85047732800     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nox216     Document Type: Article

References (41)

1. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1-iv62.
2. Stupp R, Hegi ME, Mason WP, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
3. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
4. Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995;51:167-223.
5. Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res. 1990;233(1-2):117-126.
6. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNArepair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350-1354.
7. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
8. Brennan CW, Verhaak RG, McKenna A, et al; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
9. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995;6(10):1251-1259.
10. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009;16(6):748-754.
11. Weller M, Butowski N, Tran DD, et al; ACT IV trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017;18(10):1373-1385.
12. Wick W, Gorlia T, Bady P, et al. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clin Cancer Res. 2016;22(19):4797-4806.
13. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011;71(12):4055-4060.
14. Herrlinger U, Schäfer N, Steinbach JP, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol. 2016;34(14):1611-1619.
15. Nabors LB, Fink KL, Mikkelsen T, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015;17(5):708-717.
16. Wick W, Steinbach JP, Platten M, et al. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro Oncol. 2013;15(10):1405-1412.
17. Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients\-The INFORM pilot study. Eur J Cancer. 2016;65:91-101.
18. Mikeska T, Bock C, El-Maarri O, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007;9(3):368-381.
19. Morris TJ, Butcher LM, Feber A, et al. ChAMP: 450k chip analysis methylation pipeline. Bioinformatics. 2014;30(3):428-430.
20. Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4):547-560.
21. Sahm F, Schrimpf D, Jones DT, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131(6):903-910.
22. Hertenstein A, Jones D, Sahm F, et al. Umbrella protocol for phase I/ IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N2M2). J Clin Oncol. 2016;34(15 suppl):doi: 10.1200/JCO.2016.34.15suppl.TPS2084.
23. INFORM. INFORM registry webpage. http://www.dkfz.de/en/inform/ index.html.
24. Wick W, Weller M, van den Bent M, et al. MGMT testing\-The challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014;10(7):372-385.
25. Wiestler B, Capper D, Hovestadt V, et al. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro Oncol. 2014;16(12):1630-1638.
26. Alexandrov LB, Nik-Zainal S, Wedge DC, et al; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421.
27. International Cancer Genome Consortium PedBrain Tumor P. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med. 2016;22(11):1314-1320.
28. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6):810-817.
29. Malhotra A, Lindberg M, Faust GG, et al. Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms. Genome Res. 2013;23(5):762-776.
30. Furgason JM, Koncar RF, Michelhaugh SK, et al. Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma. Oncoscience. 2015;2(7):618-628.
31. MolecularNeuropathology. Platform for next generation neuropathology. https://www.molecularneuropathology.org/mnp.
32. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425-437.
33. Sturm D, Orr BA, Toprak UH, et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell. 2016;164(5):1060-1072.
34. Verhaak RG, Hoadley KA, Purdom E, et al; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
35. Felsberg J, Rapp M, Loeser S, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009;15(21):6683-6693.
36. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol. 2004;108(6):467-470.
37. Behling F, Barrantes-Freer A, Skardelly M, et al. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol. 2016;11(1):55.
38. Hatae R, Hata N, Suzuki SO, et al. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. Neuropathology. 2017;37(3):191-199.
39. Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337(6099): 1231-1235.
40. Kessler T, Sahm F, Sadik A, et al. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Neuro Oncol. 2018;20(3):367-379.
41. Wick W, Fricke H, Junge K, et al. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res. 2014;20(24):6304-6313.